Cadila says no observation by USFDA on Ahmedabad R&D facility
Shares of Cadila Healthcare slipped 2% in the last hour of the trading session on the BSE. "USFDA inspected the Pharmaceutical Technology Centre (PTC), the company's state-of-the-art R&D facility located at Ahmedabad, dedicated to new product development of various niche dosage forms including solid oral, parenteral, pulmonary, oncology, ointment & creams and transdermal, from March 18 to March 22, 2019," the company said in the BSE filing.
At the end of the inspection, no observations (483) have been issued, the company added.
Zydus gets final nod from USFDA for Lurasidone Hydrochloride tablets
Zydus Cadila has received the final approval from the USFDA to market Lurasidone Hydrochloride Tablets USP (US RLD - Latuda Tablets), in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. It will be manufactured at the group manufacturing facility at SEZ, Ahmedabad, as per BSE filing added.
The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there).
Lupin launches generic Levothyroxine Sodium Tablets USP
Pharma major Lupin Limited (Lupin) announced the launch of Levothyroxine Sodium Tablets USP, having received approval from the USFDA earlier.
Lupin Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc Synthroid Tablets, as per BSE filing. It is indicated for:
Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Fitch cuts India GDP growth forecast for FY20 on weak momentum
Fitch Ratings has cut India economic growth forecast for the next financial year starting April 1, to 6.8% from its previous estimate of 7%, on weaker than expected momentum in the economy, as per media reports.
Fitch also slashed GDP growth forecast for current fiscal ending March 2019 to 6.9% from 7.2% projected in the December edition, the report added.
Tata Power SED bags contract from Ministry of Defence worth Rs1,200cr
Tata Power Strategic Engineering Division (Tata Power SED) announced the signing of an important deal with the Ministry of Defence, Government of India, to supply 23 ship-borne 3D Air Surveillance Radars to the Indian Navy over the next 10 years.
The contract, estimated value is about Rs1200cr, was signed under the Buy & Make (India) category of the Defence Procurement Procedure (DPP) 2013 that will be offering the Indian Navy a proven solution, with a production arrangement in India under Transfer of Technology (ToT) and thereby furthering substantive self-reliance for India defence requirements.
Financial Advisory Company in Indore, Stock Advisory Company in Indore, Equity Tips, FreeTrading Tips , MCX Tips, sebi registered advisory company, Intraday stock tips, Free commodity tips
0 comments:
Post a Comment